We report the first mutational study of thymidine kinase 1 (TK1) performed in human solid tumors. We sequenced cDNAs representing the complete coding region of TK1 in human breast (n=22) and colorectal (n=26) cancer. Codon 106 near the ATP binding site constantly differed (ATG → GTG; Met → Val) from the one deposited by Bradshaw and Deininger in the Genbank database (Accession number NM_003258). Silent polymorphisms at codon 11 (CCC → CCT; Pro → Pro) and codon 75 (GCG → GCA; Ala → Ala) were frequently detected in tumors as well as in normal tissues. In breast cancer the two polymorphisms were observed in 63.6% of the samples analyzed. No significant association could be found between polymorphisms and TK activity. In colorectal cancer the incidence of the two changes was 73.1% and 69.2%, respectively. Interestingly, one colon cancer with high cytosolic TK activity displayed two missense mutations located in and near the putative phosphorylation site by tyrosine kinase (s) (TAT → CAT; Tyr → His) and by cAMP-, cGMPdependent protein kinase (TAC → TGC; Tyr → Cys), respectively; adjacent normal mucosa showed no mutation. This may open new avenues that imply TK1 activity in tumor cell proliferation. (Int J Biol Markers 2003; 18: 1-6)
INTRODUCTION
By converting deoxythymidine to deoxythymidine monophosphate, thymidine kinase (TK) (EC 2.7.1.21; ATP: thymidine 5'-phosphotransferase) activity is involved in the salvage synthesis of pyrimidine. The cytosolic TK1 isoenzyme has been associated with cell division whereas the mitochondrial TK2 isoenzyme is cell cycle independent (1) . The human TK1 gene is located on chromosome 17q25 (2) and is organized into seven exons (3) .
In breast (4) and colorectal cancer (5) TK activity has been linked to the synthesis of the TK1 isoenzyme. In breast carcinomas TK1 is one of the strongest prognostic markers described for the natural history of the tumors (6) (7) (8) (9) (10) . In colorectal cancer thymidine uptake by cancer cells has been associated with a poor prognosis (11) . The long arm of chromosome 17, which carries the gene for TK1, has been found to be frequently duplicated in colon cancers with high TK activity, irrespective of whether the overall chromosomal pattern was mainly affected by losses or gains (12) . Measurement of TK1 in serum could be useful for monitoring the response to surgery of different types of cancer (13) including cancer of the breast (14) . It has also been suggested that intratumoral TK activity may circumvent pharmacological inhibition (5-fluorouracil, methotrexate) of de novo DNA synthesis and represents an interesting target for new cancer therapies (15) .
As somatic mutations may be a critical step in tumor development and considering the prevailing role of TK1 for tumor cell DNA synthesis, we screened breast and colorectal cancers by TK1 cDNA-sequencing analysis. This is the first time that TK1 cDNA has been sequenced in human solid tumors.
METHODS
This study included 22 primary breast cancers and 26 primary colorectal carcinomas. Tumor samples obtained by surgical resection were histologically examined by a pathologist at the time of surgery and stored at -80°C until processing. For one colon cancer (# 10 LC), normal mucosa (# 10 NL) adjacent to the tumor was simultaneously obtained. One patient with rectal cancer (# 26 REC) also underwent liver metastasectomy (# 26 MET). Normal breast tissue obtained by reduction mammoplasty (n=1), placenta (n=1), and MCF-7 cells were also analyzed. The MCF-7 cell line derived from human breast adenocarcinoma was obtained from Dr. M. Lippman (NIH, Bethesda).
Breast cancers
Breast cancer patients ranged in age from 36 to 84 years (median 50). Axillary lymph node status was assessed by histological examination; nine (40.9%) patients were node negative, six (27.3%) had one to three involved lymph nodes, and seven (31.8%) had more than four involved nodes. The pathological size of eight of the tumors (36.4%) was less than 20 mm. Ten tumors (45.5%) were grade II and 12 (54.5%) were grade III according to the Scarff Bloom and Richardson classification (16) .
Colorectal cancers
Patients with colorectal cancer ranged in age from 32 to 84 years (median 65) and comprised 11 (42.3%) men and 15 (57.7%) women. Nine (34.6%) cancers were from the right segment of the colon, eight (30.8%) from the left segment, and nine (34.6%) from the rectum. The tumors were histologically classified according to Dukes' stage modified by Astler and Coller (17) ; six (23.1%) lesions were stage A, eight (30.8%) stage B, nine (34.6%) stage C and three (11.5%) stage D. Most of the tumors (n=20, 76.9%) were well differentiated.
Sequence-based analysis of human TK1
Total RNA was prepared using the acid guanidinium isothiocyanate/phenol chloroform procedure (18) . The RNA samples were subsequently treated with 30 U ribonuclease-free desoxyribonuclease I (Roche Molecular Biochemicals, Meylan, France) to prevent any contamination by genomic DNA. Total RNA (2 µg) was reverse transcribed into cDNA using 1 µg hexamers (Pharmacia Biotech, Orsay, France) and the Moloney Murine Leukemia Virus reverse transcriptase, as described by the manufacturer (Life Technology Inc., Paris, France).
In order to analyze the entire open reading frame of TK1, a full-length cDNA was amplified using the synthetic primers 5'-ACTTACTGCGGGACGGCC-3' (57 bases upstream of the start codon) and 5'-AGATAAGCCC-CTGGGATCCA-3' (50 bases downstream of the stop codon). The Expand Long Template PCR system (Roche Molecular Biochemicals, Meylan, France) was used. PCR conditions were as follows: 94°C for 5 min; 35 cycles of 94°C for 30 sec, 58°C for 30 sec, and 68°C for 30 sec; and final elongation at 68°C for 10 min. The amplified fragments were sequenced on both strands using the ABI PRISM Dye Terminator d-rhodamine method (PE Biosystems, Foster City, USA) with 25 cycles (50°C for 5 sec, 60°C for 4 min and 96°C for 10 sec). Two overlapping primer pairs were used; for exons 1-5: 5'-ACTCGGGTTCGTGAACTTCC-3' (forward) and 5'-CCATCCAGTGCAGCCAC-3' (reverse), producing a 406 bp amplimer; for exons 5-7: 5'-GGGAAGACCG-TAATTGTGGC-3' (forward) and 5'-TCCAGTAGGCG-GCAGTGG-3' (reverse), with a product size of 409 bp. The sequencing products were analyzed using a 377 DNA Sequencer (PE Biosystems, Foster City, USA). Nucleotide changes that result in amino-acid modifications were considered as mutations and were confirmed by sequencing the cloned cDNA in the laboratories of Marseille and Montpellier.
Measurement of TK activity
TK activity was measured in the cytosol fraction prepared in Tris buffer (10 mM Tris-HCl, 1.5 mM EDTA, 10 mM Na2MoO4, 0.5 mM dithiothreitol, 10% glycerol, pH 7.4). A radioenzymatic phosphorylation assay (TK-REA, Sangtec Medical, Bromma, Sweden) optimized to detect the TK1 isoenzyme was used, as previously described (19) .
Statistical methods
The results of sequence-based analysis of TK1 gene and TK activity were compared using the Mann-Whitney U test. Two-sided p-values below 0.05 were considered significant.
RESULTS AND DISCUSSION
Here we report the first mutational study of the TK1 cDNA sequence performed in human malignancies. Figure 1 is a schematic representation of the structure of the TK1 cDNA (Genbank, Accession number (ACN) NM_003258) described by Brashaw and Deininger (20) and used as a reference, relative to the organization of the human TK1 gene and the position of the protein functional domains. Codon 1 corresponds to the start of translation (ATG). Tables I and II show the results obtained in breast and colorectal cancers, respectively, with specific alterations in the nucleotide and amino acid sequences, and the codon locations. Sequence analyses in normal breast In all breast and colorectal tumors analyzed, codon 106 of exon 5 (ATG → GTG) was found to be different from the one reported by Bradshaw and Deininger (20) , changing Met to Val near the binding site of ATP. A similar change was observed for cDNAs prepared from normal breast tissue, MCF-7 cells, placenta, liver metastasis and normal colon tissue. Our data agree with those of Berenstein et al (21) who recently reported the change from Met to Val in lymphocytes from healthy donors, leukemic cell lines and fibroblasts, and with the sequence that has been deposited by Strausberg in Genbank (ACN BC006484) for the Mammalian Gene Collection project. It has been demonstrated that recombinant lymphocyte TK1 Val has the same enzymatic and oligomerization properties as endogenous human lymphocyte TK1, while recombinant TK1 Met differs conspicuously (21) . Val residue has been localized at the corresponding site in other species, such as mouse (Genbank, ACN NM_009387) and chicken (Genbank, ACN X60380), and has also been found in EST sequences (Genbank, ACN AA284454, AA310784, AA351658, AA223113, H33613, T99993 and H42170). Our data thus finally agree with the evolutionary conservation of the TK1 gene (22) . TK1 sequence analysis also revealed silent polymorphism at codon 11 of exon 1 (CCC → CCT; Pro → Pro) and codon 75 of exon 4 (GCG → GCA; Ala → Ala). In breast cancers the two polymorphisms were always associated; the polymorphisms at codon 11 and codon 75 were detected in 63.6% (14/22) of the tumors analyzed. No significant associations could be found between polymorphisms and TK activity (Tab. I). In colorectal cancers the incidence of the two changes was 73.1% (19/26) and 69.2% (18/26), respectively; one colorectal tumor (# 8 RC) only displayed a change at codon 11. The MCF-7 cells did not show any polymorphism. Normal breast tissue, normal colon mucosa and placenta exhibited both polymorphisms, suggesting no relationship of these two changes with cancer. The two polymorphisms (CCC → CCT at codon 11 and GCG → GCA at codon 75) observed in the normal colon mucosa (# 10 NL) were not detected in the corresponding tumor (# 10 LC). Similar polymorphisms (CCC → CCT at codon 11 and GCG → GCA at codon 75) were observed in the liver metastasis (# 26 MET) and the primary tumor (# 26 REC). The polymorphisms at codon 11 and codon 75 were reported by Berenstein et al (21) in lymphocytes and cell lines with additional silent nucleotide changes that were not found here.
One out of 26 colorectal tumors (# 10 LC) displayed a missense mutation in both codon 55 of exon 3 (TAT → CAT; Tyr → His) and codon 189 of exon 7 (TAC → TGC; Tyr → Cys). These two mutations have not been previously described. The modified amino acids are located in and near the putative phosphorylation site by tyrosine kinase (s) and by cAMP-, cGMP-dependent protein kinase, respectively. Adjacent normal colon mucosa from the same patient (# 10 NL) displayed no mutations. It is thus likely that these mutations are tumor associated. A high TK cytosolic activity (1132 mU/mg protein) has been found in the tumor # 10 LC as compared to the distribution observed in the general population of patients treated for colorectal cancer in our institution (median 216 mU/mg protein) (not shown). Patient 10 was a young male (age 36 years) who showed tumor progression during first-line chemotherapy (5-fluorouracil and folinic acid). The presence of mutations in the TK1 phosphorylation sites might affect the post-translational modifications of TK1 protein and result in an enhanced enzyme activity. No evidence for the presence of TK1 mutation could be found in breast cancers. TK1 may, however, be mutated only in a restricted subset of tumors, which were not screened in our relatively small population. Further study will determine whether taking TK1 mutations into account may be important for treatment decisions in colorectal carcinomas. It will also be of interest to investigate splice site mutations by sequencing at the genomic level and to analyze other mechanisms of gene inactivation, e.g. gene methylation and loss of heterozygosity.
In conclusion, our data clearly show that in breast and colorectal cancers position 106 of the TK1 cDNA sequence differs from the one reported by Bradshaw and Deininger (20) . TK1 is the site of infrequent mutations in colon cancers, whereas polymorphisms are frequently observed in both colon and breast tumors; the functional significance of these findings should be analyzed in future studies.
